2.4.1.9 Html 247 369 1 true 82 0 false 6 false false R1.htm 000 - Disclosure - Document And Entity Information Sheet http://www.oncothyreon.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.oncothyreon.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.oncothyreon.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Parentheticals) false false R4.htm 003 - Statement - Consolidated Statements of Operations Sheet http://www.oncothyreon.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations false false R5.htm 004 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.oncothyreon.com/role/ConsolidatedComprehensiveIncome Consolidated Statements of Comprehensive Loss false false R6.htm 005 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.oncothyreon.com/role/ShareholdersEquityType2or3 Consolidated Statements of Stockholders' Equity false false R7.htm 006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals) Sheet http://www.oncothyreon.com/role/ShareholdersEquityType2or3_Parentheticals Consolidated Statements of Stockholders' Equity (Parentheticals) false false R8.htm 007 - Statement - Consolidated Statements of Cash Flows Sheet http://www.oncothyreon.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows false false R9.htm 008 - Disclosure - Note 1 - Description of Business Sheet http://www.oncothyreon.com/role/Note1DescriptionofBusiness Note 1 - Description of Business false false R10.htm 009 - Disclosure - Note 2 - Significant Accounting Policies Sheet http://www.oncothyreon.com/role/Note2SignificantAccountingPolicies Note 2 - Significant Accounting Policies false false R11.htm 010 - Disclosure - Note 3 - Fair Value Measurements Sheet http://www.oncothyreon.com/role/Note3FairValueMeasurements Note 3 - Fair Value Measurements false false R12.htm 011 - Disclosure - Note 4 - Property and Equipment Sheet http://www.oncothyreon.com/role/Note4PropertyandEquipment Note 4 - Property and Equipment false false R13.htm 012 - Disclosure - Note 5 - Acquisition Sheet http://www.oncothyreon.com/role/Note5Acquisition Note 5 - Acquisition false false R14.htm 013 - Disclosure - Note 6 - Share Capital Sheet http://www.oncothyreon.com/role/Note6ShareCapital Note 6 - Share Capital false false R15.htm 014 - Disclosure - Note 7 - Share-based Compensation Sheet http://www.oncothyreon.com/role/Note7SharebasedCompensation Note 7 - Share-based Compensation false false R16.htm 015 - Disclosure - Note 8 - Collaborative and License Agreements Sheet http://www.oncothyreon.com/role/Note8CollaborativeandLicenseAgreements Note 8 - Collaborative and License Agreements false false R17.htm 016 - Disclosure - Note 9 - Net Investment and Other Income (Expense) and Interest Expense Sheet http://www.oncothyreon.com/role/Note9NetInvestmentandOtherIncomeExpenseandInterestExpense Note 9 - Net Investment and Other Income (Expense) and Interest Expense false false R18.htm 017 - Disclosure - Note 10 - Income Tax Sheet http://www.oncothyreon.com/role/Note10IncomeTax Note 10 - Income Tax false false R19.htm 018 - Disclosure - Note 11 - Contingencies, Commitments, and Guarantees Sheet http://www.oncothyreon.com/role/Note11ContingenciesCommitmentsandGuarantees Note 11 - Contingencies, Commitments, and Guarantees false false R20.htm 019 - Disclosure - Note 12 - Subsequent Events Sheet http://www.oncothyreon.com/role/Note12SubsequentEvents Note 12 - Subsequent Events false false R21.htm 020 - Disclosure - Note 13 - Condensed Quarterly Financial Data (Unaudited) Sheet http://www.oncothyreon.com/role/Note13CondensedQuarterlyFinancialDataUnaudited Note 13 - Condensed Quarterly Financial Data (Unaudited) false false R22.htm 021 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.oncothyreon.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) false false R23.htm 022 - Disclosure - Note 2 - Significant Accounting Policies (Tables) Sheet http://www.oncothyreon.com/role/Note2SignificantAccountingPoliciesTables Note 2 - Significant Accounting Policies (Tables) false false R24.htm 023 - Disclosure - Note 3 - Fair Value Measurements (Tables) Sheet http://www.oncothyreon.com/role/Note3FairValueMeasurementsTables Note 3 - Fair Value Measurements (Tables) false false R25.htm 024 - Disclosure - Note 4 - Property and Equipment (Tables) Sheet http://www.oncothyreon.com/role/Note4PropertyandEquipmentTables Note 4 - Property and Equipment (Tables) false false R26.htm 025 - Disclosure - Note 5 - Acquisition (Tables) Sheet http://www.oncothyreon.com/role/Note5AcquisitionTables Note 5 - Acquisition (Tables) false false R27.htm 026 - Disclosure - Note 6 - Share Capital (Tables) Sheet http://www.oncothyreon.com/role/Note6ShareCapitalTables Note 6 - Share Capital (Tables) false false R28.htm 027 - Disclosure - Note 7 - Share-based Compensation (Tables) Sheet http://www.oncothyreon.com/role/Note7SharebasedCompensationTables Note 7 - Share-based Compensation (Tables) false false R29.htm 028 - Disclosure - Note 9 - Net Investment and Other Income (Expense) and Interest Expense (Tables) Sheet http://www.oncothyreon.com/role/Note9NetInvestmentandOtherIncomeExpenseandInterestExpenseTables Note 9 - Net Investment and Other Income (Expense) and Interest Expense (Tables) false false R30.htm 029 - Disclosure - Note 10 - Income Tax (Tables) Sheet http://www.oncothyreon.com/role/Note10IncomeTaxTables Note 10 - Income Tax (Tables) false false R31.htm 030 - Disclosure - Note 11 - Contingencies, Commitments, and Guarantees (Tables) Sheet http://www.oncothyreon.com/role/Note11ContingenciesCommitmentsandGuaranteesTables Note 11 - Contingencies, Commitments, and Guarantees (Tables) false false R32.htm 031 - Disclosure - Note 13 - Condensed Quarterly Financial Data (Unaudited) (Tables) Sheet http://www.oncothyreon.com/role/Note13CondensedQuarterlyFinancialDataUnauditedTables Note 13 - Condensed Quarterly Financial Data (Unaudited) (Tables) false false R33.htm 032 - Disclosure - Note 2 - Significant Accounting Policies (Details) Sheet http://www.oncothyreon.com/role/Note2SignificantAccountingPoliciesDetails Note 2 - Significant Accounting Policies (Details) false false R34.htm 033 - Disclosure - Note 2 - Significant Accounting Policies (Details) - Amortized Cost, Unrealized Gains or Losses, and Estimated Fair Value of Cash, Cash Equivalents and Investments Sheet http://www.oncothyreon.com/role/AmortizedCostUnrealizedGainsorLossesandEstimatedFairValueofCashCashEquivalentsandInvestmentsTable Note 2 - Significant Accounting Policies (Details) - Amortized Cost, Unrealized Gains or Losses, and Estimated Fair Value of Cash, Cash Equivalents and Investments false false R35.htm 034 - Disclosure - Note 2 - Significant Accounting Policies (Details) - Summary of Available-for-Sale Securities by Contractual Maturity Sheet http://www.oncothyreon.com/role/SummaryofAvailableforSaleSecuritiesbyContractualMaturityTable Note 2 - Significant Accounting Policies (Details) - Summary of Available-for-Sale Securities by Contractual Maturity false false R36.htm 035 - Disclosure - Note 2 - Significant Accounting Policies (Details) - Property and Equipment Estimated Useful Lives Sheet http://www.oncothyreon.com/role/PropertyandEquipmentEstimatedUsefulLivesTable Note 2 - Significant Accounting Policies (Details) - Property and Equipment Estimated Useful Lives false false R37.htm 036 - Disclosure - Note 2 - Significant Accounting Policies (Details) - Accumulated Other Comprehensive Loss Sheet http://www.oncothyreon.com/role/AccumulatedOtherComprehensiveLossTable Note 2 - Significant Accounting Policies (Details) - Accumulated Other Comprehensive Loss false false R38.htm 037 - Disclosure - Note 3 - Fair Value Measurements (Details) Sheet http://www.oncothyreon.com/role/Note3FairValueMeasurementsDetails Note 3 - Fair Value Measurements (Details) false false R39.htm 038 - Disclosure - Note 3 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value Sheet http://www.oncothyreon.com/role/FinancialAssetsandLiabilitiesMeasuredatFairValueTable Note 3 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value false false R40.htm 039 - Disclosure - Note 3 - Fair Value Measurements (Details) - Estimated Fair Value of Warrants Accounted for as Liabilities Sheet http://www.oncothyreon.com/role/EstimatedFairValueofWarrantsAccountedforasLiabilitiesTable Note 3 - Fair Value Measurements (Details) - Estimated Fair Value of Warrants Accounted for as Liabilities false false R41.htm 040 - Disclosure - Note 3 - Fair Value Measurements (Details) - Change in Fair Value of the Warrant Liability Sheet http://www.oncothyreon.com/role/ChangeinFairValueoftheWarrantLiabilityTable Note 3 - Fair Value Measurements (Details) - Change in Fair Value of the Warrant Liability false false R42.htm 041 - Disclosure - Note 4 - Property and Equipment (Details) Sheet http://www.oncothyreon.com/role/Note4PropertyandEquipmentDetails Note 4 - Property and Equipment (Details) false false R43.htm 042 - Disclosure - Note 4 - Property and Equipment (Details) - Cost, Accumulated Depreciation and Amortization and Net Carrying Value of Property and Equipment Sheet http://www.oncothyreon.com/role/CostAccumulatedDepreciationandAmortizationandNetCarryingValueofPropertyandEquipmentTable Note 4 - Property and Equipment (Details) - Cost, Accumulated Depreciation and Amortization and Net Carrying Value of Property and Equipment false false R44.htm 043 - Disclosure - Note 5 - Acquisition (Details) Sheet http://www.oncothyreon.com/role/Note5AcquisitionDetails Note 5 - Acquisition (Details) false false R45.htm 044 - Disclosure - Note 5 - Acquisition (Details) - Allocation of Purchase Price of Assets Acquired and Liabilities Assumed Sheet http://www.oncothyreon.com/role/AllocationofPurchasePriceofAssetsAcquiredandLiabilitiesAssumedTable Note 5 - Acquisition (Details) - Allocation of Purchase Price of Assets Acquired and Liabilities Assumed false false R46.htm 045 - Disclosure - Note 5 - Acquisition (Details) - Changes in the Carrying Amount of Goodwill Sheet http://www.oncothyreon.com/role/ChangesintheCarryingAmountofGoodwillTable Note 5 - Acquisition (Details) - Changes in the Carrying Amount of Goodwill false false R47.htm 046 - Disclosure - Note 5 - Acquisition (Details) - Unaudited Pro Forma Financial Information Sheet http://www.oncothyreon.com/role/UnauditedProFormaFinancialInformationTable Note 5 - Acquisition (Details) - Unaudited Pro Forma Financial Information false false R48.htm 047 - Disclosure - Note 6 - Share Capital (Details) Sheet http://www.oncothyreon.com/role/Note6ShareCapitalDetails Note 6 - Share Capital (Details) false false R49.htm 048 - Disclosure - Note 6 - Share Capital (Details) - Summary and Changes of Outstanding Warrants Sheet http://www.oncothyreon.com/role/SummaryandChangesofOutstandingWarrantsTable Note 6 - Share Capital (Details) - Summary and Changes of Outstanding Warrants false false R50.htm 049 - Disclosure - Note 6 - Share Capital (Details) - Summary Information Regarding Warrants Outstanding Sheet http://www.oncothyreon.com/role/SummaryInformationRegardingWarrantsOutstandingTable Note 6 - Share Capital (Details) - Summary Information Regarding Warrants Outstanding false false R51.htm 050 - Disclosure - Note 6 - Share Capital (Details) - Shares Underlying Outstanding Warrants Classified as Liabilities and Equity Sheet http://www.oncothyreon.com/role/SharesUnderlyingOutstandingWarrantsClassifiedasLiabilitiesandEquityTable Note 6 - Share Capital (Details) - Shares Underlying Outstanding Warrants Classified as Liabilities and Equity false false R52.htm 051 - Disclosure - Note 6 - Share Capital (Details) - Reconciliation of the Numerators and Denominators of Basic and Diluted Loss Per Share Sheet http://www.oncothyreon.com/role/ReconciliationoftheNumeratorsandDenominatorsofBasicandDilutedLossPerShareTable Note 6 - Share Capital (Details) - Reconciliation of the Numerators and Denominators of Basic and Diluted Loss Per Share false false R53.htm 052 - Disclosure - Note 6 - Share Capital (Details) - Shares Excluded from Diluted Loss Per Share Calculation Sheet http://www.oncothyreon.com/role/SharesExcludedfromDilutedLossPerShareCalculationTable Note 6 - Share Capital (Details) - Shares Excluded from Diluted Loss Per Share Calculation false false R54.htm 053 - Disclosure - Note 7 - Share-based Compensation (Details) Sheet http://www.oncothyreon.com/role/Note7SharebasedCompensationDetails Note 7 - Share-based Compensation (Details) false false R55.htm 054 - Disclosure - Note 7 - Share-based Compensation (Details) - Summary of the Status of the Option Plan Sheet http://www.oncothyreon.com/role/SummaryoftheStatusoftheOptionPlanTable Note 7 - Share-based Compensation (Details) - Summary of the Status of the Option Plan false false R56.htm 055 - Disclosure - Note 7 - Share-based Compensation (Details) - Weighted Average Assumptions Sheet http://www.oncothyreon.com/role/WeightedAverageAssumptionsTable Note 7 - Share-based Compensation (Details) - Weighted Average Assumptions false false R57.htm 056 - Disclosure - Note 7 - Share-based Compensation (Details) - Summary of the Status of the RSU Plan Sheet http://www.oncothyreon.com/role/SummaryoftheStatusoftheRSUPlanTable Note 7 - Share-based Compensation (Details) - Summary of the Status of the RSU Plan false false R58.htm 057 - Disclosure - Note 8 - Collaborative and License Agreements (Details) Sheet http://www.oncothyreon.com/role/Note8CollaborativeandLicenseAgreementsDetails Note 8 - Collaborative and License Agreements (Details) false false R59.htm 058 - Disclosure - Note 9 - Net Investment and Other Income (Expense) and Interest Expense (Details) Sheet http://www.oncothyreon.com/role/Note9NetInvestmentandOtherIncomeExpenseandInterestExpenseDetails Note 9 - Net Investment and Other Income (Expense) and Interest Expense (Details) false false R60.htm 059 - Disclosure - Note 9 - Net Investment and Other Income (Expense) and Interest Expense (Details) - Investments and Other Income (Expense) Sheet http://www.oncothyreon.com/role/InvestmentsandOtherIncomeExpenseTable Note 9 - Net Investment and Other Income (Expense) and Interest Expense (Details) - Investments and Other Income (Expense) false false R61.htm 060 - Disclosure - Note 10 - Income Tax (Details) Sheet http://www.oncothyreon.com/role/Note10IncomeTaxDetails Note 10 - Income Tax (Details) false false R62.htm 061 - Disclosure - Note 10 - Income Tax (Details) - Benefit (Provision) for Income Taxes Applying the Statutory Federal Income Tax Sheet http://www.oncothyreon.com/role/BenefitProvisionforIncomeTaxesApplyingtheStatutoryFederalIncomeTaxTable Note 10 - Income Tax (Details) - Benefit (Provision) for Income Taxes Applying the Statutory Federal Income Tax false false R63.htm 062 - Disclosure - Note 10 - Income Tax (Details) - Net Deferred Tax Assets Sheet http://www.oncothyreon.com/role/NetDeferredTaxAssetsTable Note 10 - Income Tax (Details) - Net Deferred Tax Assets false false R64.htm 063 - Disclosure - Note 10 - Income Tax (Details) - Uncertain Tax Positions Sheet http://www.oncothyreon.com/role/UncertainTaxPositionsTable Note 10 - Income Tax (Details) - Uncertain Tax Positions false false R65.htm 064 - Disclosure - Note 11 - Contingencies, Commitments, and Guarantees (Details) Sheet http://www.oncothyreon.com/role/Note11ContingenciesCommitmentsandGuaranteesDetails Note 11 - Contingencies, Commitments, and Guarantees (Details) false false R66.htm 065 - Disclosure - Note 11 - Contingencies, Commitments, and Guarantees (Details) - Minimum Payments, Operating Lease Sheet http://www.oncothyreon.com/role/MinimumPaymentsOperatingLeaseTable Note 11 - Contingencies, Commitments, and Guarantees (Details) - Minimum Payments, Operating Lease false false R67.htm 066 - Disclosure - Note 12 - Subsequent Events (Details) Sheet http://www.oncothyreon.com/role/Note12SubsequentEventsDetails Note 12 - Subsequent Events (Details) false false R68.htm 067 - Disclosure - Note 13 - Condensed Quarterly Financial Data (Unaudited) (Details) Sheet http://www.oncothyreon.com/role/Note13CondensedQuarterlyFinancialDataUnauditedDetails Note 13 - Condensed Quarterly Financial Data (Unaudited) (Details) false false R69.htm 068 - Disclosure - Note 13 - Condensed Quarterly Financial Data (Unaudited) (Details) - Quarterly Financial Data Sheet http://www.oncothyreon.com/role/QuarterlyFinancialDataTable Note 13 - Condensed Quarterly Financial Data (Unaudited) (Details) - Quarterly Financial Data false false All Reports Book All Reports Element onty_ProceedsFromIssuanceOfCommonStockGross had a mix of decimals attribute values: -6 -5. Element us-gaap_BusinessCombinationAcquisitionRelatedCosts had a mix of decimals attribute values: -6 -5. Element us-gaap_CommonStockValue had a mix of decimals attribute values: -3 0. Element us-gaap_FairValueAdjustmentOfWarrants had a mix of decimals attribute values: -5 -3. Element us-gaap_GainsLossesOnExtinguishmentOfDebt had a mix of decimals attribute values: -5 -3. Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 -3. Element us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock had a mix of decimals attribute values: -5 -3. Element us-gaap_RepaymentsOfDebt had a mix of decimals attribute values: -5 -3. Element us-gaap_ResearchAndDevelopmentExpense had a mix of decimals attribute values: -5 -3. 'Monetary' elements on report '007 - Statement - Consolidated Statements of Cash Flows' had a mix of different decimal attribute values. 'Monetary' elements on report '032 - Disclosure - Note 2 - Significant Accounting Policies (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '043 - Disclosure - Note 5 - Acquisition (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '053 - Disclosure - Note 7 - Share-based Compensation (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '057 - Disclosure - Note 8 - Collaborative and License Agreements (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '058 - Disclosure - Note 9 - Net Investment and Other Income (Expense) and Interest Expense (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '064 - Disclosure - Note 11 - Contingencies, Commitments, and Guarantees (Details)' had a mix of different decimal attribute values. Process Flow-Through: 001 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 002 - Statement - Consolidated Balance Sheets (Parentheticals) Process Flow-Through: Removing column 'Jun. 06, 2014' Process Flow-Through: Removing column 'Jun. 05, 2014' Process Flow-Through: 003 - Statement - Consolidated Statements of Operations Process Flow-Through: 004 - Statement - Consolidated Statements of Comprehensive Loss Process Flow-Through: 006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals) Process Flow-Through: 007 - Statement - Consolidated Statements of Cash Flows onty-20141231.xml onty-20141231.xsd onty-20141231_cal.xml onty-20141231_def.xml onty-20141231_lab.xml onty-20141231_pre.xml true true